Astellas Pharma (4503) Financial Statements

5 Followers

Astellas Pharma Financial Overview

Astellas Pharma's market cap is currently ¥4.30T. The company's EPS TTM is ¥24.29; its P/E ratio is 15.48; and it has a dividend yield of 3.61%. Astellas Pharma is scheduled to report earnings on April 27, 2026, and the estimated EPS forecast is ¥46.61. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 26	Mar 26	Mar 25	Mar 24	Mar 23
Income Statement
Total Revenue	¥ 1.91T	¥ 2.14T	¥ 1.60T	¥ 1.52T	¥ 1.30T
Gross Profit	¥ 1.56T	¥ 1.59T	¥ 1.31T	¥ 1.23T	¥ 1.04T
Operating Income	¥ 255.67B	¥ 419.70B	¥ 178.07B	¥ 285.43B	¥ 220.02B
EBITDA	¥ 462.67B	¥ 614.29B	¥ 282.45B	¥ 337.39B	¥ 297.83B
Net Income	¥ 50.75B	¥ 291.54B	¥ 17.05B	¥ 98.71B	¥ 124.09B
Balance Sheet
Cash & Short-Term Investments	¥ 188.37B	¥ 281.61B	¥ 335.69B	¥ 376.84B	¥ 315.99B
Total Assets	¥ 3.34T	¥ 3.57T	¥ 3.57T	¥ 2.46T	¥ 2.33T
Total Debt	¥ 937.09B	¥ 565.95B	¥ 1.01T	¥ 200.01B	¥ 212.74B
Net Debt	¥ 748.71B	¥ 284.35B	¥ 670.03B	¥ -176.83B	¥ -103.24B
Total Liabilities	¥ 1.83T	¥ 1.74T	¥ 1.97T	¥ 948.56B	¥ 872.09B
Stockholders' Equity	¥ 1.51T	¥ 1.83T	¥ 1.60T	¥ 1.51T	¥ 1.46T
Cash Flow
Free Cash Flow	¥ 164.61B	¥ 508.53B	¥ 143.27B	¥ 295.88B	¥ 227.42B
Operating Cash Flow	¥ 201.61B	¥ 566.25B	¥ 181.32B	¥ 332.32B	¥ 258.16B
Investing Cash Flow	¥ -96.52B	¥ -72.78B	¥ -854.65B	¥ -89.06B	¥ -63.13B
Financing Cash Flow	¥ -261.37B	¥ -404.78B	¥ 614.06B	¥ -195.62B	¥ -216.30B

Currency in JPY

Astellas Pharma Earnings and Revenue History

Income Statement >

Astellas Pharma Debt to Assets

Balance Sheet >

Astellas Pharma Cash Flow

Cash Flow >

Astellas Pharma Forecast EPS vs Actual EPS

Earnings >